RNA-based Therapeutics and Vaccines Market

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. PMR Analysis and Recommendations

2. Market Introduction

    2.1. Market Definition

    2.2. Market Taxonomy

3. RNA-based Therapeutics and Vaccines Market Opportunity Analysis

    3.1. Macro-Economic Factors

    3.2. Opportunity Analysis

4. Market Background

    4.1. Regulatory Scenario

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunity Analysis

    4.3. Pipeline Assessment

5. Gross Domestic Product by Region & Country, 2006 – 2021

6. North America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028

    6.1. Introduction

    6.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028

        6.2.1. U.S.

        6.2.2. Canada

    6.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028

        6.3.1. RNA-based Therapeutics

            6.3.1.1. siRNA

            6.3.1.2. miRNA

        6.3.2. RNA-based Vaccines

            6.3.2.1. mRNA

    6.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028

        6.4.1. Oncology

        6.4.2. Immunology

        6.4.3. Ophthalmology

        6.4.4. Cardiovascular Diseases

        6.4.5. Infectious Diseases

        6.4.6. Genetic Diseases

        6.4.7. Others

    6.5. Drivers and Restraints – Impact Analysis

7. Latin America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028

    7.1. Introduction

    7.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028

        7.2.1. RNA-based Therapeutics

            7.2.1.1. siRNA

            7.2.1.2. miRNA

        7.2.2. RNA-based Vaccines

            7.2.2.1. mRNA

    7.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028

        7.3.1. Oncology

        7.3.2. Immunology

        7.3.3. Ophthalmology

        7.3.4. Cardiovascular Diseases

        7.3.5. Infectious Diseases

        7.3.6. Genetic Diseases

        7.3.7. Others

    7.4. Drivers and Restraints – Impact Analysis

8. Europe RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028

    8.1. Introduction

    8.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028

        8.2.1. Germany

        8.2.2. U.K.

        8.2.3. France

        8.2.4. Italy

        8.2.5. Spain

        8.2.6. Russia

        8.2.7. Rest of Europe

    8.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028

        8.3.1. RNA-based Therapeutics

            8.3.1.1. siRNA

            8.3.1.2. miRNA

        8.3.2. RNA-based Vaccines

            8.3.2.1. mRNA

    8.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028

        8.4.1. Oncology

        8.4.2. Immunology

        8.4.3. Ophthalmology

        8.4.4. Cardiovascular Diseases

        8.4.5. Infectious Diseases

        8.4.6. Genetic Diseases

        8.4.7. Others

    8.5. Drivers and Restraints – Impact Analysis

9. Asia Pacific RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028

    9.1. Introduction

    9.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028

        9.2.1. China

        9.2.2. Japan

        9.2.3. Australia & New Zealand

        9.2.4. Rest of APAC

    9.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028

        9.3.1. RNA-based Therapeutics

            9.3.1.1. siRNA

            9.3.1.2. miRNA

        9.3.2. RNA-based Vaccines

            9.3.2.1. mRNA

    9.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028

        9.4.1. Oncology

        9.4.2. Immunology

        9.4.3. Ophthalmology

        9.4.4. Cardiovascular Diseases

        9.4.5. Infectious Diseases

        9.4.6. Genetic Diseases

        9.4.7. Others

    9.5. Drivers and Restraints – Impact Analysis

10. Middle East & Africa RNA-based Therapeutics and Vaccines Opportunity Assessment 2022-2028

    10.1. Introduction

    10.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028

        10.2.1. RNA-based Therapeutics

            10.2.1.1. siRNA

            10.2.1.2. miRNA

        10.2.2. RNA-based Vaccines

            10.2.2.1. mRNA

    10.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028

        10.3.1. Oncology

        10.3.2. Immunology

        10.3.3. Ophthalmology

        10.3.4. Cardiovascular Diseases

        10.3.5. Infectious Diseases

        10.3.6. Genetic Diseases

        10.3.7. Others

    10.4. Drivers and Restraints – Impact Analysis

11. Competition Analysis

    11.1. Competition Dashboard

12. Company Profiles

    12.1. Company Deep Dive

        12.1.1. Alnylam Pharmaceuticals, Inc.

        12.1.2. Arbutus Biopharma Corp.

        12.1.3. Arrowhead Pharmaceuticals, Inc.

        12.1.4. BioNTech AG

        12.1.5. CureVac AG

        12.1.6. Dicerna Pharmaceuticals, Inc.

        12.1.7. Regulus Therapeutics, Inc.

        12.1.8. Marina Biotech, Inc.

        12.1.9. miRagen Therapeutics

        12.1.10. Moderna Therapeutics, Inc.

        12.1.11. Quark Pharmaceuticals, Inc.

        12.1.12. Santaris Pharma A/S (A Roche Company)

        12.1.13. Sylentis S.A.

13. Global RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028, By Region

    13.1. Introduction/Key Findings

    13.2. Market Size (US$ Mn) Opportunity Assessment By Region, 2022-2028

        13.2.1. North America

        13.2.2. Latin America

        13.2.3. Europe

        13.2.4. Asia Pacific Excluding China

        13.2.5. Middle East & Africa

        13.2.6. China

    13.3. Market Attractiveness Analysis By Region

14. Global Product Opportunity Assessment 2022-2028, By Product Type

    14.1. Introduction/Key Findings

    14.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Product Type, 2022-2028

        14.2.1. RNA-based Therapeutics

            14.2.1.1. siRNA

            14.2.1.2. miRNA

        14.2.2. RNA-based Vaccines

            14.2.2.1. mRNA

    14.3. Market Attractiveness Analysis By Product Type

15. Global Product Opportunity Assessment 2022-2028, By Indication Type

    15.1. Introduction/Key Findings

    15.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Indication Type, 2022-2028

        15.2.1. Oncology

        15.2.2. Immunology

        15.2.3. Ophthalmology

        15.2.4. Cardiovascular Diseases

        15.2.5. Infectious Diseases

        15.2.6. Genetic Diseases

        15.2.7. Others

    15.3. Market Attractiveness Analysis By Indication

16. Global Product Opportunity Assessment 2022-2028

    16.1. Market Opportunity Assessment By All Segment

    16.2. Absolute $ Opportunity

17. Assumption & Acronyms Used

18. Research Methodology

List Of Table

Table 1: Expenditure on Health, (% of GDP), by Country, 2013 - 2021

Table 2: Expenditure on Health, (% of GDP), by Country, 2013 - 2021

Table 3: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Country

Table 4: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type

Table 5: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication

Table 6: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type

Table 7: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication

Table 8: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Country

Table 9: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type

Table 10: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication

Table 11: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Country

Table 12: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type

Table 13: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication

Table 14: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Product Type

Table 15: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Indication

Table 16: Competitive Scenario for Hereditary ATTR Amyloidosis (Patisiran (ALN-TTR02))

Table 17: Competitive Scenario for Hemophilia A Fitusiran (ALN-AT3SC)

Table 18: Competitive Scenario for Hypercholesterolemia (Inclisiran)

Table 19: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Region

Table 20: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type

Table 21: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Indication

- List Of Chart -

Figure 1: Estimated/Actual launching of RNA Therapeutics and Vaccines and their Impact on market

Figure 2: Global RNA based Vaccines Pipeline Assessment: By Development Phase

Figure 3: Global RNA based Vaccines Pipeline Assessment: By Disease Indication

Figure 4: Global RNA based Therapeutics Pipeline Assessment: By Development Phase

Figure 5: Global RNA based Therapeutics Pipeline Assessment: By Disease Indication

Figure 6: North America RNA-based Therapeutics and Vaccines Market Share, By Country (2022)

Figure 7: North America RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2022 & 2028

Figure 8: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2022-2028

Figure 9: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2022-2028

Figure 10: Europe RNA-based Therapeutics and Vaccines Market Share, By Country (2022)

Figure 11: Europe RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2022 & 2028

Figure 12: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2022-2028

Figure 13: Asia Pacific RNA-based Therapeutics and Vaccines Market Share, By Country (2022)

Figure 14: Asia Pacific RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2022 & 2028

Figure 15: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2022-2028

Figure 16: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2022-2028

Figure 17: Global RNA-based Therapeutics and Vaccines Market Share, By Region (2028)

Figure 18: Global RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2022 & 2028, By Region

Figure 19: Global RNA-based Therapeutics and Vaccines Market Share, By Product Type (2028)

Figure 20: Global RNA-based Therapeutics and Vaccines Market Share, By RNA-based Therapeutics segment (2028)

Figure 21: Global RNA-based Therapeutics and Vaccines Market Share, By Indication (2028)

Figure 22: Global RNA-based Therapeutics and Vaccines Market Value Analysis and Opportunity Assessment, 2022-2028 (US$ Mn)

Figure 23: Global RNA-based Therapeutics and Vaccines Market Absolute $ Opportunity (US$ Mn), 2022-2028